HUTCHMED (China) (HMDCF) Gains from Investment Securities (2018 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Gains from Investment Securities came in at $11.5 million in Q2 2021, up 63.64% year-over-year from $7.1 million in Q2 2020, and down 62.19% quarter-over-quarter from $30.5 million in Q1 2021.
Analysis
HUTCHMED (China) (HMDCF) Gains from Investment Securities (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Gains from Investment Securities for 4 consecutive years, with $11.5 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Gains from Investment Securities rose 63.64% year-over-year to $11.5 million in Q2 2021; TTM through Jun 2021 was $77.4 million, a 70.86% increase from a year earlier, with the FY2025 full-year figure at $22.7 million, down 51.26% from the prior year.
- Gains from Investment Securities was $11.5 million for Q2 2021 at HUTCHMED (China), down from $30.5 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $30.5 million in Q1 2021 and troughed at $1.1 million in Q2 2019.
- A 4-year average of $14.1 million and a median of $11.6 million in 2018 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities plunged 87.49% in 2019 and soared 563.31% in 2020, its largest moves.
- Over 4 years, Gains from Investment Securities stood at $11.7 million in 2018, then fell by 14.8% to $10.0 million in 2019, then retreated by 29.22% to $7.1 million in 2020, then surged by 63.64% to $11.5 million in 2021.
- The last three Gains from Investment Securities figures came in at $11.5 million (Q2 2021), $30.5 million (Q1 2021), and $7.1 million (Q2 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 11.54 Mn |
| Mar 31, 2021 | 30.51 Mn |
| Jun 30, 2020 | 7.05 Mn |
| Mar 31, 2020 | 28.27 Mn |
| Dec 31, 2019 | 9.96 Mn |
| Jun 30, 2019 | 1.06 Mn |
| Mar 31, 2019 | 17.11 Mn |
| Dec 31, 2018 | 11.69 Mn |
| Jun 30, 2018 | 8.50 Mn |
| Mar 31, 2018 | 15.03 Mn |